Exelixis (EXEL) Stock Forecast & Price Target

EXEL Forecast - Frequently Asked Questions

What is Exelixis' forecast for 2026?

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Exelixis is $47.83, with a high forecast of $60.00 and a low forecast of $36.00.

Should I buy or sell Exelixis stock right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 2 sell ratings, 11 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EXEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EXEL, but not buy additional shares or sell existing shares.

Does Exelixis's stock price have much upside?

According to analysts, Exelixis's stock has a predicted upside of 3.51% based on their 12-month stock forecasts.

Has Exelixis been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Exelixis's stock had 2 upgrades and 1 downgrade by analysts.

What analysts cover Exelixis?

Exelixis has been rated by research analysts at Barclays, HC Wainwright, Morgan Stanley, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, Wells Fargo & Company, and Zacks Research in the past 90 days.

Do Wall Street analysts like Exelixis more than its competitors?

Analysts like Exelixis more than other "medical" companies. The consensus rating score for Exelixis is 2.39 while the average consensus rating score for "medical" companies is 2.30. Learn more on how EXEL compares to other companies.